


**Patient Assessment for Treatment  
with ER/LA Opioid Analgesia**

Module I



**Jeffrey Gudin, MD**

Director

Pain Management and Palliative Care  
Englewood Hospital and Medical Center  
Englewood, New Jersey

## Key Learning Points



1. A complete and thorough H&P including pain assessment is first step in the development of a treatment strategy for all pain patients
2. A variety of risk assessment tools are available for use in your practice, pick one you are comfortable with using that is appropriate in your practice environment
3. Special populations such as the elderly and children may require additional assessment monitoring
4. DOCUMENT all assessments, test results, patient interactions and treatment plans in your chart or EMR

## Overall Program Learning Objectives

*Upon completion of this initiative, prescribers will be better able to:*

- **Identify and define how to assess patients for treatment with ER/LA opioid analgesics**
- Demonstrate how to initiate therapy, modify dose and discontinue use of ER/LA opioid analgesics
- Recognize how to manage ongoing therapy with ER/LA opioid analgesics
- Employ patient and caregiver counseling about the safe use of ER/LA opioid analgesics, including proper storage and disposal
- Recall general and product-specific drug information concerning ER/LA opioid analgesics



## **Patient Assessment**

**W. Clay Jackson, MD, DipTh**

Clinical Assistant Professor

Family Medicine and Psychiatry

University of Tennessee College of Medicine

Memphis, Tennessee

## **Who Should Receive Opioid Therapy?**

- More long-term success has been reported in patients who are stable psychosocially and whose pain is well controlled on low-to-moderate doses of opioids
- However, the success of opioid therapy cannot be reliably predicted by type or history of pain

Breivik H. *Eur J Pain*. 2005;9(2):127-130.

## Initial Evaluation and Assessment of Pain

- Comprehensive clinical interview
  - Patient history
  - Physical examination
- Diagnostic studies
- Determination of nature of pain
  - Pain location, duration, intensity, type, patterns
  - Nociceptive, neuropathic, idiopathic components
    - Factors that reduce or intensify pain
- Assessment of comorbid states
- Impact of pain on function, mood, sleep
- Patient's expectations of treatment

Chou R, et al. *J Pain*. 2009;10(2):113-130.; Fishman S. *Responsible opioid prescribing: a physician's guide*. 2007.

## Assessment of Risk of Abuse Including Substance Use and Psychiatric History

- Thorough assessment of psychosocial and family history
- Current and prior medical/psychiatric conditions; history of chemical dependence
- Previous use of pain medication
- Social environment and home situation
- Pain-related litigation/other legal issues

Fishman S. *Responsible opioid prescribing: a physician's guide*. 2007.

## Factors Predicting Likelihood of Opioid Overuse/Misuse OR Abuse

- Nonfunctional status due to pain<sup>1</sup>
- Exaggeration of pain<sup>1</sup>
- Unclear etiology for pain<sup>1</sup>
- Age<sup>2</sup>
- Smokers<sup>2</sup>
- Poor social support<sup>3</sup>
- Polysubstance abuse<sup>3</sup>
- Psychological stress<sup>4</sup>
- Psychological disease<sup>2</sup>
- Focus on opioids<sup>1</sup>
- Preadolescent sexual abuse<sup>2</sup>

<sup>1</sup>Alturi S, et al. *Pain Physician*. 2002;5(4):447-448. <sup>2</sup>Webster LR, et al. *Pain Med*. 2005;6(6):432-442. <sup>3</sup>Dunbar SA, et al. *Pain Symptom Manage*. 1996;11(3):163-171. <sup>4</sup>Savage SR. *Clin J Pain*. 2002;18(4 Suppl):S28-S38.

## Audience Response Question

**By definition, which of the following behaviors is not categorized as misuse?**

- A. Unsanctioned use (running out early; bingeing)
- B. Accessing drugs from other sources (friend, the street, other doctors)
- C. Reluctance to use other methods of pain management
- D. Self-administration of medications to alter one's state of consciousness ("get high")

## Understanding Terminology

### Abuse

Any use of an illicit drug with the intentional self-administration of a medication for nonmedical purpose such as altering one's state of consciousness (eg, getting high). A licit substance such as alcohol also can be abused

### Addiction

A primary, chronic, neurobiologic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. Addiction is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving

### Diversion

The intentional removal of a medication from legitimate distribution and dispensing channels for illicit sale or distribution

### Misuse

Use of a medication (for a medical purpose) other than as directed or as indicated, whether willful or unintentional, and whether harm results or not

### Physical dependence

A state of adaptation that is manifested by a drug-class-specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist

### Tolerance

A state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug's effects over time

## Chronic Use of Opioids: Associated Risks

- Overdose
- Abuse
- Misuse
- Addiction
- Physical dependence
- Tolerance
- Interactions with other medications and substances
- Inadvertent exposure by others in household, especially children

Rosenblatt RA, et al. *Ann Fam Med*. 2012;10(4):300-301.

## Opioid Overdose

- Overdose with ER/LA formulations is a particular concern as most dosage units contain more opioid than immediate-release formulations

Paulozzi L. Epidemiology of the overdose epidemic. Common Threads in Pain and Addiction. Pain and Addiction Common Threads XIII. 43<sup>rd</sup> Annual Meeting of the American Society of Addiction Medicine, Atlanta, GA, April, 19, 2012.

## Opioid Naïve versus Opioid Tolerance: FDA Definition

- Patients are considered opioid tolerant if they are taking, **for 1 week or longer**, at least:
  - Oral morphine – 60 mg daily
  - Transdermal fentanyl – 25 mcg/h
  - Oral oxycodone – 30 mg daily
  - Oral hydromorphone – 8 mg daily
  - Oral oxymorphone – 25 mg daily
  - Equianalgesic daily dose of another opioid


Refer to prescribing information on which products and which doses are indicated for use only in opioid tolerant patients.  
[www.fda.gov](http://www.fda.gov). Accessed February 12, 2014.

## Responsible Opioid Prescribing

### *Patient Assessment for Treatment with ER/LA Opioid Analgesia*

#### Module I

### Abuse by Patient or Household Contacts in Accordance with the Source of Prescription Drugs



\*Wrote fake prescription, stole from doctor's office/clinic/hospital/pharmacy, or some other way.

SAMHSA. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings and Detailed Tables. [www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/Index.aspx](http://www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/Index.aspx). Accessed January 17, 2014.

### Inadvertent Exposure: Children

- In 2011, over 67% of Emergency Department visits for accidental drug ingestion involved children aged 5 and under
  - 6.7% of visits in children under 5 involved narcotic pain relievers
- Importance of counseling on safe storage/disposal
- Children are especially vulnerable



Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits [www.samhsa.gov/data/2k13/DAWN2k11ED/DAWN2k11ED.htm](http://www.samhsa.gov/data/2k13/DAWN2k11ED/DAWN2k11ED.htm). Accessed February 12, 2014.



## Risk Assessment Tools

- Risk assessment tools can be useful in evaluating potential risks of drug abuse, misuse, addiction, and diversion
- The tools differ in their formats, ease with which they may be administered, target populations, and the points during treatment when they may be most valuable

## Audience Response Question

**What tool do you currently use in your practice for risk assessment?**

- A. ORT
- B. SOAPP
- C. COMM
- D. PHQ-9
- E. I do not currently use a risk assessment tool

## Responsible Opioid Prescribing

### Patient Assessment for Treatment with ER/LA Opioid Analgesia

#### Module I

## Opioid Risk Assessment Tools:

### Questionnaires for Patients Considered for Chronic Opioid Therapy

<b>Opioid Risk Tool (ORT)</b>	<ul style="list-style-type: none"> <li>• 5 question; self-administered</li> <li>• Risk scoring: <b>0-3 low; 4-7 moderate; ≥8</b></li> </ul>
<b>Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R)</b>	<ul style="list-style-type: none"> <li>• 24 questions; usually self-administered</li> <li>• May be completed as part of an interview with a health care professional</li> <li>• Risk scoring: <b>Identifies patients as high, moderate or low risk for misuse of opioids</b></li> </ul>
<b>Diagnosis, Intractability, Risk and Efficacy Score (DIRE)</b>	<ul style="list-style-type: none"> <li>• 7 questions; administered by health care professional</li> <li>• Risk scoring: <b>total score of 7-13 not suitable for long-term opioid therapy; score of 14-21 indicate patient may be candidate for long-term opioid therapy</b></li> </ul>

Butler SF, et al. *J Pain*. 2008;9(4):360-372.; Katz NP, et al. *Clin J Pain*. 2007;23(2):103-118.; Webster LR, Webster RM. *Pain Med*. 2005;6(6):432-442.; Manchikanti L, et al. *J Opioid Manag*. 2007;3(2):89-100.

## Opioid Misuse Assessment Tools:

### Questionnaires for Patients Once Opioid Treatments Begin

<b>Pain Medication Questionnaire (PMQ)</b>	<ul style="list-style-type: none"> <li>• 26-item questionnaire; self-administered</li> <li>• Risk scoring: A total score of ≥25 is indicative of problematic use; a total score of ≥30 is indicative that patient should be monitored when prescribed opioid therapy</li> </ul>
<b>Current Opioid Misuse Measure (COMM)</b>	<ul style="list-style-type: none"> <li>• 17-item questionnaire; self-administered</li> <li>• Risk scoring: <b>A total score of ≥9 is positive for Current Opioid Misuse Measure (COMM); a total score of &lt;9 is negative for Current Opioid Misuse Measure (COMM)</b></li> </ul>
<b>Prescription Drug Use Questionnaire (PDUQ)</b>	<ul style="list-style-type: none"> <li>• 42-item questionnaire; administered by clinician</li> <li>• Risk scoring: <b>The patient answers yes and no questions about his or her pain condition, opioid use patterns, social and family factors, family history of pain and substance abuse syndromes, patient history of substance abuse, and psychiatric history</b></li> <li>• <b>A score &lt;11 'did not meet criteria for a substance disorder,' while those with a score of ≥15 'had a substance use disorder</b></li> </ul>

COMM. [www.etsu.edu/com/cme/documents/kptt2012/7-COMM\\_Final\\_SAMPLE.pdf](http://www.etsu.edu/com/cme/documents/kptt2012/7-COMM_Final_SAMPLE.pdf). Accessed February 12, 2014.; Butler SF, et al. *Pain*. 2007; 130(1-2): 144-156.

**Responsible Opioid Prescribing**  
**Patient Assessment for Treatment with ER/LA Opioid Analgesia**  
**Module I**

## Opioid Risk Tool

---

<b>Mark each box that applies</b>	<b>Female</b>	<b>Male</b>	
<b>1. Family history of substance abuse</b>			
Alcohol	<input type="checkbox"/> 1	<input type="checkbox"/> 3	<b>Administration</b> <input type="checkbox"/> Initial visit <input type="checkbox"/> Prior to opioid therapy <b>Scoring</b> <input type="checkbox"/> 0-3 (6%): low risk <input type="checkbox"/> 4-7 (28%): moderate risk <input type="checkbox"/> ≥8 (91%): high risk <small>Percentages indicate proportion of classified patients who exhibited an aberrant behavior</small>
Illegal drugs	<input type="checkbox"/> 2	<input type="checkbox"/> 3	
Prescription drugs	<input type="checkbox"/> 4	<input type="checkbox"/> 4	
<b>2. Personal history of substance abuse</b>			
Alcohol	<input type="checkbox"/> 3	<input type="checkbox"/> 3	
Illegal drugs	<input type="checkbox"/> 4	<input type="checkbox"/> 4	
Prescription drugs	<input type="checkbox"/> 5	<input type="checkbox"/> 5	
<b>3. Age (mark box if between 16 and 45 years)</b>	<input type="checkbox"/> 1	<input type="checkbox"/> 1	
<b>4. History of preadolescent sexual abuse</b>	<input type="checkbox"/> 3	<input type="checkbox"/> 0	
<b>5. Psychological disease</b>			
ADD, OCD, bipolar, schizophrenia	<input type="checkbox"/> 2	<input type="checkbox"/> 2	
Depression	<input type="checkbox"/> 1	<input type="checkbox"/> 1	
<b>Scoring totals</b>	_____	_____	

ADD=attention-deficit disorder; OCD=obsessive-compulsive disorder.  
 Webster LR, Webster RM. *Pain Med.* 2005;6(6):432-442.

## Monitoring Aberrant Behaviors and Adherence

---

Aberrant drug-related behaviors consist of a range of behaviors that suggest misuse by the patient and possibly a substance use disorder. Examples of aberrant drug-related behaviors are illustrated below

<b>Behaviors that are weaker indicators</b>	<b>Behaviors that are stronger indicators</b>
<ul style="list-style-type: none"> <li>Aggressively complaining about the need for medications/higher doses</li> <li>Drug hoarding during periods of reduced symptoms</li> <li>Requesting specific drugs</li> <li>Acquisition of similar drugs from other medical sources</li> <li>Unsanctioned dose escalation 1-2 times</li> <li>Unapproved use of the drug to treat another symptom</li> <li>Reporting psychic effects not intended by the clinician</li> </ul>	<ul style="list-style-type: none"> <li>Injection of an oral formulation</li> <li>Selling prescription drugs</li> <li>Stealing or borrowing another patient's drugs</li> <li>Obtaining prescription drugs from nonmedical sources</li> <li>Concurrent abuse of related illicit drugs</li> <li>Multiple unsanctioned dose escalations</li> <li>Recurrent prescription losses</li> </ul>

Passik SD, et al. *Oncology (Williston Park).* 1998;12:517-521, 524.

## Risk Factors for Aberrant Behaviors/Harm

Biological	Psychiatric	Social
<p>Age ≤ 45 years                      Gender                      Family history of prescription drug or alcohol abuse                      Cigarette smoking</p>	<p>Substance use disorder                      Preadolescent sexual abuse (in women)                      Major psychiatric disorder (eg, personality disorder, anxiety or depressive disorder, bipolar disorder)</p>	<p>Prior legal problems                      History of motor vehicle accidents                      Poor family support                      Involvement in a problematic subculture</p>

Katz NP, et al. *Clin J Pain.* 2007;23(2):103-118.; Manchikanti L, et al. *J Opioid Manag.* 2007;3(2):89-100.; Webster LR, Webster RM. *Pain Med.* 2005;6(6):432-442.

## Risk Groups for Therapy

Low Risk	Moderate Risk	High Risk
<ul style="list-style-type: none"> <li>• Mild-to-moderate pain</li> <li>• Absent mental health problems</li> <li>• Absent SA history</li> <li>• Strong self-esteem</li> </ul>	<ul style="list-style-type: none"> <li>• Intractable pain</li> <li>• Unrelieved stress</li> <li>• Poor coping skills</li> <li>• Inadequate social support</li> </ul>	<ul style="list-style-type: none"> <li>• Major mental health concerns</li> <li>• Personal and/or family history of SA</li> <li>• Age &lt;50</li> <li>• Smoker</li> </ul>

Webster LR, Webster RM. *Pain Med* 2005;6(6):432-442.

## Special Considerations for the Elderly Patient

- Pain in the elderly population is especially difficult given the myriad of physiological, pharmacological, and psychological aspects of caring for the geriatric patient
- Challenges related to
  - Alterations in opiate pharmacokinetics which occur with normal physiologic aging
  - Polypharmacy
  - Comorbid conditions
  - Higher risk of opioid related adverse events
  - Respiratory depression is more likely
- Requires close monitoring during treatment:
  - Initiating and titrating ER/LA opioids (starting dose should be reduced to 1/3 to 1/2 of usual dosage in debilitated non-opioid tolerant patients)
  - Special attention to development of constipation
- Pay special attention to who will be managing patient's pain



Starting doses should be reduced to 1/3 to 1/2 of usual dosage in debilitated non-opioid tolerant patients

Institute bowel prep pro-actively at the initiation of treatment

Chau DL, et al. *Clin Interv Aging*. 2008;3(2):273-278.

## Special Considerations in Choosing to Treat Children: Pediatric Patients <18 Years Old

- The safety and effectiveness of most ER/LA opioids in children younger than 18 years have not been established, and most of these agents are not indicated for children
- An exception is transdermal fentanyl, which is approved in *opioid-tolerant* children ages 2 years of age and older\*
- Pediatric pain specialists should be consulted when prescribing opioids to children for chronic pain or refer to a specialty multidisciplinary pain clinic



\*Please refer to PI for complete prescribing information. Transdermal fentanyl is approved for children ages 2 years and older who are opioid tolerant.  
Berde CB, et al. *Pediatrics*. 2012;129:354-364.

**Treating a Chronic Pain Patient with a History of Substance Abuse, Psychiatric Issues and/or Drug Related Aberrant Behaviors**

- History does not prohibit treatment with ER/LA opioid analgesics but may require additional monitoring and a clinician experienced in the management of this patient population
- May consider consultation with mental health professional and or addiction specialist

Von Korff M, et al. *Ann Intern Med.* 2011;155:325-328.


**Stratify Patients with Chronic Pain to Determine Need for Referral**

Risk Level	Management
<b>Low</b>	<ul style="list-style-type: none"><li>• Can be managed by PCP</li><li>• If aberrant behaviors are observed, consider increasing risk category</li></ul>
<b>Medium</b>	<ul style="list-style-type: none"><li>• PCP co-manages with addiction and/or pain specialists</li><li>• If aberrant behaviors are observed or persistent, consider assigning to high-risk category</li></ul>
<b>High</b>	<ul style="list-style-type: none"><li>• Opioids may not be appropriate in the PCP setting</li><li>• Refer patient to specialists in management of patients with comorbid pain and addictive disorders</li><li>• Continue to manage patient's medical care and monitor specialized care</li></ul>

Gourlay D, et al. *Pain Med.* 2005;6(2):107-112.; Gourlay D, et al. *Pain Med.* 2006;7:210-211;author reply 212.

## Principles of Patient Selection: Considerations Before an Opioid Trial

- Pain is severe and warrants around-the-clock long-term opioid treatment
- Alternative treatments have failed or no alternative therapy likely to provide benefit
- Benefits are likely to outweigh risks
- Ability of patient to adhere to the rules of therapy




Fine PG, Portenoy RK. *A Clinical Guide to Opioid Analgesia*. New York, NY: Vendome Group, 2007.

## Importance of Proper Documentation

- Adequately document all patient interactions, assessments, test results and treatment plans


## Summary



### Engage

Patient-centered care

Clinician-patient  
interaction to enhance  
health outcomes




### Educate

All treatment begins with thorough assessment

Variety of risk assessment tools available. The  
key is not which tool you use but that a  
tool/assessment is completed

Special consideration should be employed for  
the elderly and children in assessing for  
treatment of pain with an opioid analgesic

Documentation!



### Protect

Document all patient  
interactions,  
assessments, test results  
and treatment plans to  
protect your practice,  
your patients, their  
families, caregivers and  
the community

***Thank you for completing Module 1.***

***You must answer the post-test questions at the  
end of this module before moving on to  
Module 2***

***You must complete all six modules in order to  
print your CE certificate***